多重聚合酶链反应在重症肺炎患者中的诊断性能及对抗菌治疗的影响:多中心观察研究(MORICUP-PCR研究:摩洛哥ICU肺炎-PCR研究)
该多中心观察研究纳入摩洛哥12个ICU的210例需有创机械通气的成人肺炎患者(CAP 30%、VAP 58%、HAP 12%),同时用mPCR和常规微生物方法检测呼吸道样本。mPCR敏感性96.9%(95%CI 92.3-99.2%)、特异性92%(95%CI 91-93%);58%(n=122)患者据此调整抗生素,适当率从38.7%(n=83)升至67%(n=141),差值27.5%(95%CI 18.3-36.7,p<0.0001)。广义混合模型显示mPCR后适当抗生素治疗与死亡率降低相关(aOR 0.37,95%CI 0.15-0.93,p=0.038)。作者认为mPCR与经验性抗菌治疗适当率显著改善及患者结局正面影响相关。
要点
- mPCR对重症肺炎病原诊断敏感性96.9%(95%CI 92.3-99.2%)、特异性92%(95%CI 91-93%)。
- mPCR后58%(n=122)患者调整抗生素:降阶梯或停用11%(n=23)、升级26.5%(n=56)、适当性调整7.5%(n=16)、启动抗生素13%(n=27)。
- 抗菌治疗适当率从38.7%(n=83)升至67%(n=141),差值27.5%(95%CI 18.3-36.7,p<0.0001)。
- mPCR后适当抗生素治疗与死亡率降低相关(aOR 0.37,95%CI 0.15-0.93,p=0.038)。
- 研究人群为需有创机械通气的成人肺炎(CAP 30%、VAP 58%、HAP 12%),中位年龄50岁(范围33-67岁),男性66.2%。
适用人群与场景
- 摩洛哥12个ICU的成人肺炎患者,需有创机械通气,包括社区获得性肺炎(CAP,30%)、医院获得性肺炎(HAP,12%)和呼吸机相关性肺炎(VAP,58%)。
- 共纳入210例,中位年龄50岁(范围33-67岁),男性66.2%。
处置流程与药物剂量
- 对呼吸道样本同时进行mPCR和常规微生物方法检测。
- 根据mPCR结果调整经验性抗生素治疗:降阶梯或停用11%(n=23)、升级26.5%(n=56)、适当性调整7.5%(n=16)、启动抗生素13%(n=27)。
研究设计与关键结果
- 多中心观察研究,纳入12个ICU的210例需有创机械通气的成人肺炎患者,干预为无,比较mPCR与常规微生物方法。
- mPCR敏感性96.9%(95%CI 92.3-99.2%),特异性92%(95%CI 91-93%)。
- mPCR后58%(n=122)患者调整抗生素,其中降阶梯或停用11%(n=23)、升级26.5%(n=56)、适当性调整7.5%(n=16)、启动抗生素13%(n=27)。
- 抗菌治疗适当率从38.7%(n=83)升至67%(n=141),差值27.5%(95%CI 18.3-36.7,p<0.0001)。
- 广义混合模型分析显示,mPCR后适当抗生素治疗与死亡率降低相关(aOR 0.37,95%CI 0.15-0.93,p=0.038)。
证据类型、等级与局限
- 证据类型:多中心观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,mPCR的使用与经验性抗菌治疗适当率显著改善相关,且与肺炎患者结局的正面影响相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Managing severe pneumonia remains a challenge. Rapid diagnostic tests, such as multiplex polymerase chain reaction (mPCR), facilitate quick microorganism identification and may enable timely and appropriate antimicrobial therapy. However, studies from low-income countries are scarce. This study aimed to evaluate the diagnostic characteristics of mPCR and its impact on antibiotic therapy and outcomes in critically ill patients with pneumonia.
DESIGN: Multicenter observational study.
SETTING: Twelve ICUs across Morocco.
PATIENTS: Adult patients with pneumonia requiring invasive mechanical ventilation, including community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP).
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Respiratory samples were analyzed using both mPCR and conventional microbiological methods. The diagnostic performance of mPCR was evaluated, including its sensitivity and specificity. Additionally, the appropriateness of mPCR-induced modifications in empiric antibiotic therapy and their impact on patient outcomes were assessed. A total of 210 patients were included, with a median age of 50 years (range, 33-67 yr), of whom 66.2% were male. Pneumonia types were distributed as 30% CAP, 58% VAP, and 12% HAP. mPCR demonstrated a sensitivity of 96.9% (95% CI, 92.3-99.2%) and a specificity of 92% (95% CI, 91-93%). Following mPCR, antibiotic therapy modifications were observed in 58% of patients (n = 122), including de-escalation or cessation in 11% (n = 23), escalation in 26.5% (n = 56), adequacy adjustments in 7.5% (n = 16), and initiation of antibiotics in 13% (n = 27). The appropriateness of antibiotic therapy increased significantly from 38.7% (n = 83) to 67% (n = 141; difference, 27.5%; 95% CI, 18.3-36.7; p < 0.0001). Generalized mixed model analysis revealed that appropriate post-mPCR antibiotic therapy was associated with reduced mortality (adjusted odds ratio, 0.37; 95% CI, 0.15-0.93; p = 0.038).
CONCLUSIONS: Our findings suggest that the use of mPCR is associated with a significant improvement in the appropriateness of empiric antibiotic therapy and is also associated with a positive impact on the outcome of patients with pneumonia.
参考来源
- Aissaoui Y, Derkaoui A, Hachimi A, et al. Diagnostic Performance and Impact on Antimicrobial Treatment of a Multiplex Polymerase Chain Reaction in Critically Ill Patients With Pneumonia: A Multicenter Observational Study (The MORICUP-PCR Study: Morocco ICU Pneumonia-PCR study). Crit Care Explor. 2025. PMID: 39937572. doi:10.1097/CCE.0000000000001220
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。